AbbVie raises guidance as core replacements beat expectations
- Skyrizi and Rinvoq have become the main answer to Humira’s patent cliff.
- Neuroscience is now a second growth engine, growing roughly 20% in the latest quarter.
- Management raised full-year revenue guidance by $300 million after strong Q2 2026 results.
- Aesthetics is mixed with Juvederm continuing to decline due to weak consumer demand.
- The price question matters because Medicare price setting now touches Imbruvica, Vraylar, Linzess, and Botox.
The post-Humira test is being passed
AbbVie’s core story is simple. Humira is fading, but the replacement drugs are growing faster. In Q2 2026, Skyrizi sales grew 24% on an operational basis, and Rinvoq sales grew 23.7%. Humira fell 36.1% operationally, but the new immunology drugs more than covered the loss. This momentum allowed management to raise full-year revenue guidance by $300 million.
The bull case is that AbbVie has built two real growth pillars. Immunology is the first. Neuroscience is the second, with Vraylar, Botox Therapeutic, migraine drugs, and the Parkinson’s drug Vyalev. Neuroscience revenue grew roughly 20% in Q2 2026, creating a powerful second engine for the company.
The bear case is not about one problem. It is about several drags that can cap the upside. Juvederm is still weak because dermal fillers depend on consumer spending. Oncology is held back by Imbruvica, which fell 29.4% in Q2 2026 due to competition and pricing pressure. Medicare price setting is also spreading to important products, including Vraylar and Botox.
Blockbusters, payers, and patents
AbbVie makes money by selling branded medicines. These drugs are sold to wholesalers, distributors, government agencies, health care facilities, pharmacies, and doctors. In the United States, insurers and government programs have a lot of power over access and price.
The model works best when AbbVie launches a drug with strong clinical data, wins insurance coverage, expands it into more diseases, and protects it with patents. Skyrizi and Rinvoq show that playbook. They treat immune diseases such as psoriasis, Crohn’s disease, and ulcerative colitis.
The model breaks when patents expire, rivals copy the drug, or payers cut the price. Humira is the example. Biosimilars, which are close copies of biologic drugs, have pushed Humira sales down sharply. Medicare price setting under the Inflation Reduction Act adds another pressure point for older drugs.
AbbVie also uses deals to fill its pipeline. The planned acquisition of Apogee Therapeutics adds early-stage immunology assets. That can help growth, but it adds integration risk and requires ongoing capital allocation.
The drugs that matter most
Skyrizi and Rinvoq
These are AbbVie’s main post-Humira immunology drugs. In Q2 2026, Skyrizi grew 24% and Rinvoq grew 23.7% operationally.
Humira
Humira is the former flagship drug, but biosimilar competition is cutting into sales. Q2 2026 Humira revenue fell 36.1% operationally.
Neuroscience franchise
This group includes Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev. Neuroscience revenue was up about 20% in Q2 2026.
Oncology franchise
Venclexta, Elahere, and Epkinly are growing, but Imbruvica is shrinking fast. Total oncology sales were down 2.4% operationally in Q2 2026.
Aesthetics franchise
Botox Cosmetic is the lead product, while Juvederm is struggling. In Q2 2026, overall aesthetics revenue fell slightly.
Apogee pipeline assets
AbbVie plans to acquire Apogee Therapeutics to add early-stage depth to its long-term immunology pipeline.
Where Q2 2026 sales came from
AbbVie reports one global business segment. This mix groups Q2 2026 product revenue by therapy area based on recent earnings disclosures.
What could go wrong
Humira keeps falling faster than planned
Medium impact · High oddsHumira is already in steep decline because biosimilars are taking share. In Q2 2026, Humira revenue was down 36.1% on an operational basis. The risk is that payer access gets worse and the cash flow bridge from Humira shrinks faster than AbbVie expects.
Medicare price setting hits more profit pools
High impact · High oddsImbruvica is already feeling pressure from government-set Medicare prices and competition, falling 29.4% in Q2 2026. The 2025 10-K also said Vraylar, Linzess, and Botox were selected for price setting between 2026 and 2028. This matters because Vraylar and Botox sit inside AbbVie’s growth base.
Skyrizi and Rinvoq face tougher rivals
High impact · Medium oddsSkyrizi and Rinvoq are carrying the post-Humira story. If rivals take share in inflammatory bowel disease or other immune conditions, AbbVie’s growth math gets harder. The company is trying to defend its lead with new indications and easier dosing.
Aesthetics stays weak
Medium impact · High oddsAesthetics depends partly on consumers choosing to spend on procedures. That makes it exposed to weak consumer sentiment. Juvederm revenue fell 6.6% operationally in Q2 2026 because of lower demand.
In one breath
Is AbbVie still dependent on Humira?
Much less than before. Humira is still meaningful, but Skyrizi and Rinvoq are now much larger growth drivers and are offsetting the Humira decline.
Why is AbbVie’s valuation score not higher?
The business is executing well, but the stock also has visible risks. Medicare price setting, Humira erosion, debt, and weak aesthetics demand all limit how much investors may want to pay.
What is the biggest catalyst for AbbVie over the next year?
The main catalyst is execution against raised 2026 guidance. Investors will also watch Vyalev’s sales ramp, ABBV-295 obesity data, and the Apogee integration.
